BioCryst Pharmaceuticals is trading 4.02% up at $9.44 after its August 5, 2026, second-quarter results beat expectations.
- Revenue reached $218.3 million, including $55.7 million recognized from the navenibart European licensing agreement.
- Adjusted EPS was $0.30 versus a $0.16 consensus estimate.
- Management raised full-year total-revenue guidance to $690 million-$715 million, supporting the positive reaction.